Guangxi Daily: PuraPharm – the epitome of the successful companies and investors from Hong Kong and Macau in Guangxi
18 June 2013
The “Mainland China and Hong Kong Closer Economic Partnership Arrangement” (CEPA) launched by Hong Kong, Mainland and Macau has further enhanced the room for development of the investments between the three areas. There is a growing trend of potential Hong Kong and Macau companies and investors developing and investing at the Guangxi area; while Hong Kong, especially, is the largest origin of foreign investments for Guangxi; this shows that Guangxi is a place full of commercial opportunities.
PuraPharm Hong Kong set up PuraPharm (Nanning) Pharmaceutical Co. Ltd in Mainland China shortly after its establishment, and has achieved success. PuraPharm is now one of the six companies that are authorized by China to manufacture and sell concentrated Chinese Medicine granules in the country; and is also described as “the epitome of the successful companies and investors from Hong Kong and Macau in Guangxi” by the Guangxi Daily.
With the facilitation of CEPA and Pan-PRD cooperation mechanisms, the trade of cargo and services in Hong Kong, Macau and Guangxi is growing continuously. This works as a “win-win” effect, promoting the vast development at each area.